Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Translational Development Acquisition (TDAC) Common Equity (2023 - 2026)

Translational Development Acquisition's Common Equity history spans 4 years, with the latest figure at -$6.8 million for Q1 2026.

  • On a quarterly basis, Common Equity fell 14.77% to -$6.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$6.8 million, a 14.77% decrease, with the full-year FY2025 number at -$6.5 million, down 16.87% from a year prior.
  • Common Equity came in at -$6.8 million for Q1 2026, down from -$6.5 million in the prior quarter.
  • The five-year high for Common Equity was -$507658.0 in Q4 2023, with the low at -$6.8 million in Q1 2026.
  • Historically, Common Equity has averaged -$4.3 million across 4 years, with a median of -$5.9 million in 2025.
  • Biggest five-year swings in Common Equity: crashed 1110.6% in 2025 and later fell 14.77% in 2026.
  • Year by year, Common Equity stood at -$507658.0 in 2023, then tumbled by 1002.63% to -$5.6 million in 2024, then decreased by 16.87% to -$6.5 million in 2025, then fell by 4.3% to -$6.8 million in 2026.
  • Business Quant data shows Common Equity for TDAC at -$6.8 million in Q1 2026, -$6.5 million in Q4 2025, and -$6.4 million in Q3 2025.